GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TScan Therapeutics Inc (NAS:TCRX) » Definitions » Shareholder Yield %

TScan Therapeutics (TScan Therapeutics) Shareholder Yield % : -14.32% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is TScan Therapeutics Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, TScan Therapeutics's Shareholder Yield % was -14.32%.


TScan Therapeutics Shareholder Yield % Historical Data

The historical data trend for TScan Therapeutics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TScan Therapeutics Shareholder Yield % Chart

TScan Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shareholder Yield %
- - 0.78 -69.50 -19.88

TScan Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.50 -91.18 -56.38 -60.28 -19.88

Competitive Comparison of TScan Therapeutics's Shareholder Yield %

For the Biotechnology subindustry, TScan Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TScan Therapeutics's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where TScan Therapeutics's Shareholder Yield % falls into.



TScan Therapeutics Shareholder Yield % Calculation

TScan Therapeutics's Shareholder Yield % for the quarter that ended in Dec. 2023 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0 %+0 %+-19.88 %
=-19.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


TScan Therapeutics  (NAS:TCRX) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


TScan Therapeutics Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of TScan Therapeutics's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


TScan Therapeutics (TScan Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Executives
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Leiden Dworak officer: Chief Accounting Officer C/O TSCAN THERAPEUTICS, INC., 880 WINTER STREET, WALTHAM MA 02451
Lynx1 Capital Management Lp 10 percent owner 151 CALLE DE SAN FRANCISCO, SUITE 200 PMB 1237, SAN JUAN PR 00901-1607
Weston Nichols 10 percent owner C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Brian M. Silver officer: Chief Financial Officer C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Debora Barton officer: Chief Medical Officer C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
David P Southwell director, officer: Chief Executive Officer C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014

TScan Therapeutics (TScan Therapeutics) Headlines

From GuruFocus

TScan Therapeutics Announces Closing of Public Offering

By sperokesalga sperokesalga 06-01-2023

TScan Therapeutics Announces CEO Transition

By sperokesalga sperokesalga 03-31-2023

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

By Stock market mentor Stock market mentor 01-05-2023